The rapid evolution of biosimilar regulation over the past decade is reflected in EMA’s Concept paper proposing a revision of the Guideline on Similar Biological Medicinal Products, which was last revised in 2015. EMA states that the revision is needed because “major progress has been made in the analytical sciences and regulatory field of biosimilars”.
Linnea Brodin
Finance Manager
BSc Business and Economics
Linnea is our Finance Manager. She has a BSc in Business and Economics from Södertörns University and has previously worked in the accounts payable department at Huddinge Kommun.
Staffan Thunell
Founding partner
BSc Economics and BA
Staffan has a long background in entrepreneurship within the life science industry. He has 20+ years experience from positions as Founder, Chairman, CEO and CFO within medical affairs consulting and small pharma. Previously Staffan worked in executive positions in big pharma and specialty pharma companies.